Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
February 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology
Emerging Therapies
Novel Target: RARA Agonist plus Azacitidine Active in Relapsed or Refractory Acute Myeloid Leukemia
Phoebe Starr
Read More
Emerging Therapies
Magrolimab, First CD47 Antibody, Shows Promise in Combination with Azacitidine in Unfit Patients with Acute Myeloid Leukemia
Wayne Kuznar
Read More
Emerging Therapies
Oral Vodobatinib Elicits Durable Responses in Heavily Pretreated Patients with Chronic Myeloid Leukemia
Chase Doyle
Read More
Pevonedistat plus Azacitidine Combination Improves Outcomes versus Azacitidine Monotherapy in High- Risk Myelodysplastic Syndromes
Wayne Kuznar
Read More
Value-Based Care
Financial Toxicity Intervention in Patients with Hematologic Malignancies Effective, Improves Adherence and Quality of Life
Chase Doyle
Read More
FDA Approvals
,
Multiple Myeloma
Xpovio Approved for Patients with Relapsed or Refractory Multiple Myeloma
Read More
FDA Approvals
,
Lung Cancer
Tagrisso Approved as Adjuvant Therapy for NSCLC with EGFR Mutations
Read More
FDA Approvals
,
Lymphoma
Xalkori Approved for Anaplastic Large-Cell Lymphoma and ALK Mutation in Young Patients
Read More
Emerging Therapies
First-Line Mosunetuzumab Safe and Effective in Older Patients with Diffuse Large B-Cell Lymphoma
Chase Doyle
Read More
Value-Based Care
ASH 2020 Presidential Symposium Highlights Innovations Aimed to Improve Patient Access to Treatment
Wayne Kuznar
Read More
1
2
3
Page 2 of 3
Results 11 - 20 of 27